Kiran Kumar Jagarlamudi received his initial Bachelor's Degree in Veterinary Sciences from the College of Veterinary Sciences, Hyderabad, India. He became Master in Animal Science at the Swedish Agricultural University in Uppsala Sweden, and obtained the degree of PhD in Veterinary Medicine (Biochemistry) earlier this year at the Swedish Agricultural University.
"Dr Kiran Kumar Jagarlamudi has an extensive research background in projects related to our product portfolio. These include developing an antibody based assay and evaluation of detecting TK 1 protein in serum, serum TK 1 activity and STK1 protein determination, as well as developing an ELISA based assay for routine clinical practice of TK1 as a biomarker " says Jan Stålemark, AroCell's CEO. "We are delighted that Kiran Kumar Jagarlarmudi will join our team as Product Specialist and contribute in this role with his unique expertise in research."
For additional information please contact:
Jan Stålemark, CEO AroCell AB (publ)
About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology are based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com. AroCell AB is listed at Aktie Torget (AROC) and has about 2 250 shareholders.